Figure 2.

Biomarkers for patients 1–3 before and after initiation of FK506. (A) Bone morphogenetic protein receptor 2 (BMPR2) messenger RNA (mRNA)/glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in peripheral blood mononuclear cells (PBMCs) of healthy control subjects (ctrl) at baseline (B) (n = 12) and three patients (n = 3) at baseline and 3, 6, and 12 months (Mon). The red dashed line indicates the time FK506 was stopped in patient 3. (B) Id1/GAPDH mRNA in PBMCs. (C) SMURF-1/GAPDH mRNA in PBMCs. (D) IL-6 plasma levels via ELISA. (E) LIMK1/GAPDH mRNA in PBMCs. (F) Cofilin-1 (CFL1)/GAPDH mRNA in PBMCs. (G and H) miR21/RNU48 and miR27a/RNU48 RNA expression in PBMCs, respectively. CT = cycle threshold; Id1 = inhibitor of differentiation 1; SMURF-1 = SMAD-specific E3 ubiquitin protein ligase 1; LIMK1 = LIM domain kinase 1; miR = microRNA; RNU48 = small nucleolar RNA, C/D box 48.